口服甲福明通过调节肠视网轴来抑制胆道新血管化
Jason Y Zhang1, Jason Xiao1, Bingqing Xie2
1Pritzker School of Medicine, University of Chicago, Chicago, Illinois, United States.
Investigative ophthalmology & visual science
|December 18, 2023
概括
甲福明通过改变肠道微生物群来减少胆道新血管化 (CNV),这表明了与年龄相关的黄斑变性 (AMD) 的新疗法. 这项研究强调了肠道微生物群.
科学领域:
- 眼科医生 眼科 眼科
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 新出现的证据表明,甲福明可以预防与年龄相关的黄斑变性 (AMD).
- 梅特福林抗衰老作用背后的机制尚未完全理解,肠道微生物组是拟议的途径.
- 冠状腺新血管化 (CNV) 是晚期新血管性AMD的标志.
研究的目的:
- 为了研究口服甲福尔对激光诱导的CNV的影响.
- 分析甲胺对视网膜色素表皮质 (RPE) /状体转录组的影响.
- 检查甲福明对肠道微生物群的组成和功能的影响.
主要方法:
- 雄性小鼠接受了口服的甲福明或载体,随后是激光诱导的CNV.
- 通过免疫染来评估CNV大小和免疫细胞透率.
- 进行了RPE/choroid的RNA测序,16SrRNA测序,射门甲基因组学和便样本的代谢物分析. 研究重复在无菌和移植微生物群的小鼠中进行.
主要成果:
- 甲福明治疗显著减少了中枢神经瘤的大小和巨/微细胞透.
- 基因表达分析显示,在接受甲福林治疗的小鼠中,亲血管性因素的下调.
- 甲胺改变了肠道微生物组合,增加了有益的细菌 (Bifidobacterium,Akkermansia) 和关键代谢物 (丁酸盐,酸盐,胆酸). 甲胺对 CNV 的作用取决于肠道微生物群的存在.
结论:
- 口服甲福明可以抑制 CNV,这是晚期新血管AMD 中的一个关键病变.
- 这些效应通过调节肠道微生物群来调节.
- 甲胺对肠道微生物群的影响表明,它可能是AMD的潜在治疗策略.
更多相关视频
06:51Retinal Explant of the Adult Mouse Retina as an Ex Vivo Model for Studying Retinal Neurovascular Diseases
Published on: December 9, 2022
4.2K
12:28Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
Published on: March 12, 2022
3.6K
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
179
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
179
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Open Angle Glaucoma: Treatment
455
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
455
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
